A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.

@article{Laine1999ART,
  title={A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.},
  author={L Laine and Sean P Harper and Thomas Simon and Raymond J. Bath and Jesper Johanson and Howard Schwartz and S E Stern and Hui Quan and Jim Bolognese},
  journal={Gastroenterology},
  year={1999},
  volume={117 4},
  pages={776-83}
}
BACKGROUND & AIMS Prostaglandin production in the normal gastrointestinal tract, believed to be critical for mucosal integrity, is mediated by cyclooxygenase (COX)-1, whereas prostaglandin production at inflammatory sites seems to occur via induction of COX-2. We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 117 extracted citations

Ulzerierende Ileokolitis unter NSAR-Therapie

View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…